Novartis Investigative Site

Khoudh 123

2 studies enrolling now · 5 studies all time

What they study most

Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic, Myelodysplastic Syndromes, Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Sickle Cell Disease, Sickle Cell Disease (SCD)

Studies at this site

• Asciminib Roll-over Study — Recruiting now
• Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — Recruiting now
• Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients — Running, not enrolling
• A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) — Running, not enrolling
• Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) — Stopped early